Evidence map›Paper›PMID 33401386›Full record

ReviewMicroorganisms2021

Type IA Topoisomerases as Targets for Infectious Disease Treatments.

Ahmed Seddek, Thirunavukkarasu Annamalai, Yuk-Ching Tse-Dinh

Open access · goldAbstract readReview
In one paragraph

Review in Microorganisms, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Small Molecule Inhibitors ofInternational journal of molecular sciences · 2024
    Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Ahmed SeddekDepartment of Chemistry and Biochemistry, Florida International University, Miami, FL 33199, USA.ORCID 0000-0003-4490-002X
Thirunavukkarasu AnnamalaiDepartment of Chemistry and Biochemistry, Florida International University, Miami, FL 33199, USA.
Yuk-Ching Tse-DinhDepartment of Chemistry and Biochemistry, Florida International University, Miami, FL 33199, USA.ORCID 0000-0002-5616-5176
Florida International University · US

Funding

Supplement for undergraduate research participant to promote diversityR01GM054226 · NIGMS · NEW YORK MEDICAL COLLEGE · PI TSE-DINH, YUK-CHING · 1996 to 2020
$4.6M
Bacterial cell killing topoisomerase I--DNA lesionR01AI069313 · NIAID · NEW YORK MEDICAL COLLEGE · PI TSE-DINH, YUK-CHING · 2006 to 2014
$3.4M
Structure, Mechanism and Interactions of Type IA TopoisomerasesR35GM139817 · NIGMS · FLORIDA INTERNATIONAL UNIVERSITY · PI TSE-DINH, YUK-CHING · 2021 to 2025
$1.6M
NIAID NIH HHS R01 AI069313NIGMS NIH HHS R01 GM054226NIGMS NIH HHS R35 GM139817NIH HHS R01 GM054226
6 · The paper itself

Abstract

Infectious diseases are one of the main causes of death all over the world, with antimicrobial resistance presenting a great challenge. New antibiotics need to be developed to provide therapeutic treatment options, requiring novel drug targets to be identified and pursued. DNA topoisomerases control the topology of DNA via DNA cleavage-rejoining coupled to DNA strand passage. The change in DNA topological features must be controlled in vital processes including DNA replication, transcription, and DNA repair. Type IIA topoisomerases are well established targets for antibiotics. In this review, type IA topoisomerases in bacteria are discussed as potential targets for new antibiotics. In certain bacterial pathogens, topoisomerase I is the only type IA topoisomerase present, which makes it a valuable antibiotic target. This review will summarize recent attempts that have been made to identify inhibitors of bacterial topoisomerase I as potential leads for antibiotics and use of these inhibitors as molecular probes in cellular studies. Crystal structures of inhibitor-enzyme complexes and more in-depth knowledge of their mechanisms of actions will help to establish the structure-activity relationship of potential drug leads and develop potent and selective therapeutics that can aid in combating the drug resistant bacterial infections that threaten public health.

Indexed as

antimicrobial resistancedrug targetstopoisomerase

Identifiers

PMID33401386
PMCPMC7823277
OpenAlexW3114867570

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.